Progen gets in synth
Wednesday, 02 July, 2008
Brisbane biotech Progen Pharmaceuticals (ASX: PGL) has spun out its manufacturing business into a wholly-owned subsidiary.
The new subsidiary will be called PharmaSynth, and will be responsible for completing Progen's PI-88 manufacturing process.
It will also offer process development and manufacturing services to the biotechnology industry.
Progen's former director of manufacturing operations, Les Tillack, is the new company's CEO.
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
